1055710-50-3

Upstream product

• 1301170-22-8 C₆H₃BrClFMg 
• 147804-30-6 1-oxa-6-aza-spiro-[2.5]octane-6-caboxylic acid tert-butyl ester 
• 1996-30-1 2-bromo-4-chloro-1-fluorobenzene 

Downstream Products

• 71916-97-7 5-chloro-2,3-dihydrospiro 
• 644968-71-8 N-(2-{[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-methoxyphenyl)acetamide 
• 644968-75-2 N-(2-{[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)acetamide 
• 1427190-05-3 C₂₄H₃₀ClN₃O₄ 
• 1427190-11-1 C₃₄H₄₆ClN₃O₈ 

Relevant academic research and scientific papers

Spirocyclic compounds, potent CCR1 antagonists

Conformationally constrained spirocycles (17-23) and (31-36) were synthesised. In vitro data revealed that these compounds are CCR1 antagonists with sub-nanomolar potency. In a functional assay 22, 23 and 36 inhibited CCR1 mediated chemotaxis with an ICs

NOVEL COMPOUNDS

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, t, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their

NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, p, X, Y, R3, R4, t and, R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

NOVEL COMPOUNDS

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their prepa